UNANIMOUS: Bayer wins FDA panel backing for riociguat in PAH/CTEPH
This article was originally published in Scrip
Executive Summary
Bayer HealthCare handily won the backing of a US FDA panel of experts on 6 August for the company's experimental medicine riociguat as a treatment for two rare forms of pulmonary hypertension – pulmonary arterial hypertension (PAH), or WHO Group 1, and chronic thromboembolic pulmonary hypertension (CTEPH), or WHO Group 4 – which can lead to progressive right ventricular dysfunction and failure, ultimately resulting in premature death.